Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q1 EPS of ($1.01), $0.17 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $27.61 million versus the consensus estimate of $17.5 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.